Agranulocytosis, acquired
VA disability rating criteria for Agranulocytosis, acquired under Diagnostic Code 7702. The VA assigns ratings of 10%, 30%, 60%, 100% based on the severity and functional impact of your condition.
Rating Criteria
Requiring continuous medication (e.g., antibiotics) for control; or requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl
Requiring intermittent myeloid growth factors to maintain ANC greater than 1000/µl; or infections recurring, on average, at least once per 12-month period but less than once every three months per 12-month period
Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or continuous immunosuppressive therapy such as cyclosporine to maintain absolute neutrophil count (ANC) greater than 500/microliter (µl) but less than 1000/µl; or infections recurring, on average, at least once every three months per 12-month period
Requiring bone marrow transplant; or infections recurring, on average, at least once every six weeks per 12-month period
Get a Personalized Rating Analysis
AIDEN can analyze your specific symptoms, identify secondary connections, and help you understand what rating you may qualify for based on your medical evidence.
Talk to AIDEN